FibroGen, Inc., (NASDAQ: FGEN), today announced the dosing of the first patient in the LAPIS Phase 3 clinical study of pamrevlumab in patients with unresectable locally advanced pancreatic cancer (LAPC). “Patients with unresectable locally advanced pancreatic cancer...
REDWOOD SHORES, Calif., Oct. 23, 2019 /PRNewswire/ — Oracle Health Sciences, a leader in eClinical technology and Phlexglobal, pioneers in the provision of Trial Master File (TMF) technology and services for the global life sciences industry, have announced...
BeyondSpring Inc. (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company has enrolled its first patient in a Phase 3, Study 106, clinical trial with its lead...
$90 million award expected from the National Institute of Aging and the National Heart, Lung, & Blood Institute to fund largest pragmatic trial with placebo-controlled drug assignment to date In the first statin trial with a non-cardiovascular primary outcome,...
Sofinnova Partners – Life sciences-focused venture capital firm based in Paris, closed its latest fund, Sofinnova Capital IX, oversubscribed at €333 million. The firm now has more than €2B under management with more than €1B raised in the last four years across its...
Email
Text